136 results about "Pirfenidone" patented technology

The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of pirfenidone. The present invention further provides methods of treating end-stage or advanced Type II diabetes, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone and insulin.

The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.

The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.

The present invention provides methods of treating a fibrotic disorder. The methods generally involve administering an effective amount of IFN-γ and an effective amount of pirfenidone or a pirfenidone analog.

A pharmaceutical liquid composition containing the Pirfenidone in a very high concentration of more or less 25% by weight can be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether. Even when the liquid medicinal compositions are stored for a long period of time, the Pirfenidone will not be recrystallized with a good chemical and physical stability. Furthermore, the liquid compositions are little irritating to the wounds on the mucous membrane of the skin and suitable for the manufacture of pharmaceutical formulations to be administered either via the oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, injection or intravenous drip.

The present invention provides methods for treating alphavirus infections; methods of treating hepatitis C virus (HCV) infections; methods of treating West Nile virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering effective amounts of an interferon receptor agonist and pirfenidone in combination therapy.

The present invention is directed to a novel use of pyridone derivatives such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and/or therapeutic effects of the pyridone derivatives make it possible to increase therapeutic dosages of the cytotoxic agent, thereby enhancing the therapeutic efficacy of the cytotoxic agent and radiation therapy.

The invention relates to the usage of pirfenidone for treating hepatic injury and necrosis and acute lung injury, more specifically the invention relates to the application of pirfenidone in abatement of symptoms for patients with hepatic injury, necrosis and acute lung injury, and in lowering mortality rate. The invention also provides the medicinal composition for treating hepatic injury, necrosis and acute lung injury.

The invention relates to a pharmaceutical composition for treating hepatic fibrosis and a preparation method thereof. The pharmaceutical composition is a formulation prepared from a main ingredient and pharmaceutically acceptable auxiliary materials, wherein the main ingredient comprises 100-300 parts of pirfenidone and 50-150 parts of inosine. The formulation of pirfenidone and inosine is stable in quality, controllable, safe and effective. In clinic, the formulation is mainly used for the treatment of diseases of hepatic fibrosis, cirrhosis, liver cancer, and the like.

A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne.

The present invention belongs to the technical field of medicine, and particularly relates to a solid drug composition containing pirfenidone, and a preparation process thereof. The drug composition contains pirfenidone, a binder and a disintegrating agent, and can be prepared into tablets, granules and capsules.

The invention discloses a peritoneal dialysis solution which comprises 0.01-5%w/v pirfenidone. Through a good deal of experimental research and analysis, the process that the 0.01-5%w/v pirfenidone is added to a conventional peritoneal dialysis solution so that peritoneum fibrosis caused by high-concentration glucose in an existing peritoneal dialysis solution can be remarkably blocked and delayed is found out.

The invention provides a pirfenidone-contained gel composition and a preparation method thereof. The pirfenidone-contained gel composition comprises pirfenidone and other pharmaceutically acceptable accessories. The invention further illuminates the clinical use method and the applications of the preparation mode.

The invention relates to a preparing method for pirfenidone. The method includes the steps that under the action of an acid catalyst, 2-pentenenitrile is used for reacting with trimethyl/triethyl orthoformate to generate 2-methyl-1-alkoxy-4-cyano-1,3-butadiene (II), and 2-methyl-1-alkoxy-4-cyano-1,3-butadiene (II) and aniline are condensed and then hydrolyzed to obtain pirfenidone. The used raw materials are low in price and easy to obtain, the process flow is short, and the preparing method is easy to operate, environmentally friendly, high in reaction selectivity and high in product yield and purity.

The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD/NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFkB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD/NASH and advanced liver fibrosis.

The invention relates to a solid preparation comprising pirfenidone as an active component and application thereof. The solid preparation is an oral solid preparation prepared by carrying out pharmaceutical technology on pirfenidone and pharmaceutically acceptable auxiliary materials. The solid preparation disclosed herein has the advantages of stable and controllable quality, safety and effectiveness, and is mainly clinically used as a medicine for treating idiopathic pulmonary fibrosis to mitigate the symptoms and reduce the mortality.

The invention provides a medical composite containing pirfenidone, which is characterized by containing 20-90% of pirfenidone, 10-50% of filler, 1-10% of disintegrating agent, 0.1-8% of adhesive and 0.2-3% of lubricant.

The disclosure relates to granulate formulations of pirfenidone and methods of making such formulations.